Hereditary breast and ovarian cancer in Asia:: Genetic epidemiology of BRCA1 and BRCA2

被引:111
作者
Liede, A
Narod, SA
机构
[1] Univ Toronto, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada
[2] Cedars Sinai Med Ctr, Womens Canc Res Inst, Los Angeles, CA 90048 USA
关键词
Asia; breast cancer; ovarian cancer; BRCA1; BRCA2; founder effect; founder mutations; China; Japan; Philippines; Singapore; India; Pakistan; Iran;
D O I
10.1002/humu.10154
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Ethnic differences in cancer incidence and mortality result from differences in genetic and epidemiologic risk factors. Mutations in BRCA1 and BRCA2 account for a small proportion of all breast cancer cases, but for a much higher proportion of cases with a strong family history of breast or ovarian cancer. Germline mutations in BRCA1 and BRCA2 have been identified in individuals of many races and ethnic groups and the frequency of mutations varies between these groups. Some of the differences in cancer risk between populations may be the result of founder mutations in these genes. The cost and time required for mutation analysis are reduced considerably when founder mutations are identified for a specific ethnic group. The BRCA2 999de15 mutation in Iceland and three BRCA mutations in Ashkenazi Jews are well characterized. However, considerably less is known about the contribution of mutations in the BRCA1 and BRCA2 genes outside of European groups. Studies, conducted on the Asian populations described here have expanded our current knowledge of genetic susceptibility and its contribution to breast and ovarian cancer rates in Asian populations.
引用
收藏
页码:413 / 424
页数:12
相关论文
共 91 条
[1]   The 185delAG BRCA1 mutation originated before the dispersion of Jews in the Diaspora and is not limited to Ashkenazim [J].
Bar-Sade, RB ;
Kruglikova, A ;
Modan, B ;
Gak, E ;
Hirsh-Yechezkel, G ;
Theodor, L ;
Novikov, I ;
Gershoni-Baruch, R ;
Risel, S ;
Papa, MZ ;
Ben-Baruch, G ;
Friedman, E .
HUMAN MOLECULAR GENETICS, 1998, 7 (05) :801-805
[2]  
Bhurgri Y, 2000, INT J CANCER, V85, P325, DOI 10.1002/(SICI)1097-0215(20000201)85:3&lt
[3]  
325::AID-IJC5&gt
[4]  
3.0.CO
[5]  
2-J
[6]  
*BIC, 2002, BREAST CANC INF COR
[7]   Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer [J].
Chappuis, PO ;
Hamel, N ;
Paradis, AJ ;
Deschênes, J ;
Robidoux, A ;
Potvin, C ;
Cantin, J ;
Tonin, P ;
Ghadirian, P ;
Foulkes, WD .
CLINICAL GENETICS, 2001, 59 (06) :418-423
[8]  
Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO
[9]  
2-Z
[10]   A unique BRCA1 mutation identified in Mongolia [J].
Elit, L ;
Jack, E ;
Kwan, E ;
Baigal, G ;
Narod, S .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2001, 11 (03) :241-243